1 **Recombinant AhpC antigen from *Mycobacterium bovis* boosts BCG-primed**
2 **immunity in mice**

3 **Abstract**

4 Tuberculosis (TB) is still one of the most common infectious diseases around the World,
5 despite the widespread use of BCG (bacille Calmette-Guerin) strain of *Mycobacterium*
6 *bovis* as a vaccine. This vaccine does not always protect people from TB, and thus new
7 effective vaccines or vaccination strategies are being investigated. In this study, alkyl
8 hydroperoxide reductase (AhpC) from *M. bovis* was evaluated as a new candidate vaccine
9 antigen against TB in BALB/c mice model. The *ahpC* gene was amplified from *M.bovis*
10 genome, cloned, and expressed in *Escherichia coli*. Vaccine antigen AhpC was
11 formulated with Montanide ISA 61 VG, an oil-based emulsion adjuvant. Both IgG and
12 IL-12 responses were observed in mice after administering the formulation both as a
13 subunit vaccine alone and also as a booster vaccine for BCG immunization. However, a
14 long-lasting response was observed when AhpC formulation was used as a booster (for
15 BCG-primed immunization) as compared to been used as a subunit vaccine alone. In
16 short, these findings suggested that AhpC has the potential to be used as a booster vaccine
17 candidate for BCG-primed immunization.

18 Keywords: Subunit vaccine, tuberculosis, prime-boost vaccination, recombinant protein

19

20 **1. Introduction**

21 Tuberculosis (TB) is an infectious disease that is primarily caused by the
22 inhalation of particles containing bacilli within the *Mycobacterium tuberculosis* complex
23 (MTBC) (Kanipe and Palmer, 2020). While *M. tuberculosis* mainly infects the human

host, the primary causative agent for TB in the family *Bovidae* is *M. bovis* (Rodriguez-Campos et al., 2014). The susceptibility of humans to TB caused by *M. bovis* is attributed to its zoonotic character (Michel et al., 2010). In addition to person-to-person transmission (Evans et al., 2007; Sunder et al., 2009)., *M. bovis* is also transmitted in humans by consumption of unpasteurized or contaminated dairy products or inhalation of aerosols containing bacillus (Grange, 2001).

Since 1931, *M. bovis* Bacillus Calmette-Guérin (BCG) vaccine has been used as the only licensed vaccine against TB since 1931. Although BCG vaccine is widely used worldwide, high variability in its efficacy (%0-80), ineffectiveness against pulmonary TB in adults (Colditz, 1994), and safety risks due to the possibility of mutation to its virulent form (Fatima et al.,2020) clearly demonstrate the need for a more effective vaccine protecting against all forms of TB in all age groups. Currently, several vaccines are under clinical trials either as potential alternatives for BCG, or as booster vaccines (Whitlow et al., 2020).

Data obtained from virulence gene identification studies is playing an essential role both in the discovery of new drug targets and in the development of novel TB vaccine candidates. The virulence factor proteins of *M. bovis* inhibit the macrophages' antimicrobial attacks and enhances the resistance of the bacilli against the first immune attack of the macrophages (via oxidative and nitrosative stress responses, phagosome arresting, and apoptosis inhibition) (Forrellad et al., 2013). A typical example of this is, alkyl hydroperoxide reductase C (Rv2428, AhpC), a member of the peroxiredoxin family, that catalyzes the detoxification reaction of organic peroxides into less reactive derivatives. Thus, AhpC can protect the microbial pathogen against both oxidative and nitrosative stresses (Echeverria-Valencia et al., 2018).

Sequence similarity of *ahpC* genes from different *Mycobacterium* species including *M. bovis*, *M. tuberculosis, M. ulcerans*, *M. africanum*, *M. smegmatis*, *M. sinense*, and *M. leprae* was shown in the paper of Wong et al (2013). The protective effect of AhpC against oxidative stress responses of the host immune cells, and correlation between ahpC gene expression and bacterial virulence were extensively investigated by other researchers (Wilson and Collins, 1996; Wilson et al., 1998). On the other hand Verma et al., (2021) revealed *kasA* and a*hpC* genes as potential drug targets due to their roles in drug resistance. Considering these features of the AhpC, it was thought that it could be both a vaccine and also a drug candidate.

In this study, *ahpC* gene was amplified from *M.bovis* and heterologously produced in *E.coli* BL21(DE3) expression system. Then, purified recombinant AhpC protein was formulated with an oil-based adjuvant. We investigated the immunostimulatory effect of the antioxidant enzyme AhpC both as a subunit vaccine alone and a booster vaccine after BCG prime immunization in BALB/c mice groups.

2. Materials and Methods

2.1. Bacterial strains, media, and plasmids

Escherichia coli strains DH5α (Novagen, Germany) and BL21 (DE3) (ATCC, USA) were used for cloning and expression of the gene *ahpC*, respectively. LB Broth with agar (Miller) and LB Broth (Miller) media were used for the cultivation of *E.coli* strains. Isolated and purified genomic DNA of *M. bovis* (ATCC 35743, GenBank CP003494.1, USA) was kindly provided by Assoc. Prof. Dr. Alpaslan Alp (Hacettepe University Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey). The pGEMT Easy (Promega, USA) and pET28a(+) (Novagen, Germany) plasmids were

used for gene cloning and recombinant protein expression, respectively. Protino® Ni-TED kit (Macherey-Nagel, Germany) was used to purify His-tagged recombinant protein.

2.2. PCR amplification of *ahpC* gene

The genomic DNA of *M. bovis* was used as the template for amplification of *ahpC* gene (588 bp). The nucleotide sequence corresponding to *ahpC* gene was amplified using polymerase chain reaction (PCR) with the following two pairs of gene-specific primers, *ahpC*F: 5'– ggatccatgccactgctaaccattg-3' (*BamH*I site underlined) and *ahpC*R: 5'-aagcttggccgaagccttgag - 3' (*Hind*III site underlined). All chemical and biological reagents were purchased from ThermoScientific. PCR mix composed of 2.5 mM $MgCl_2$, 0,2 µM of primers, 1 ng template DNA, 0,6 mM dNTP mix (Cat. No. R0192), 1 × *Taq* buffer (with KCl, without $MgCl_2$) and 0,1 U *Taq* DNA polymerase (Cat. No. EP402) was prepared in a total volume of 25 µL. The cycling program was set as 94 °C for 10 min, 30 cycles of amplification (94 °C for 1 min, 52 °C for 30 s, 72 °C for 1 min), and at 72 °C for 10 min. PCR products were analyzed by electrophoresis using 1% (w/v) agarose gel.

2.3. Construction of recombinant plasmids

pGEMT Easy Vector System (Promega, WI, USA) was used for the ligation of PCR products. The ligation reaction was performed according to the instructions of the manufacturer, and plasmids transformed into *E. coli* DH5α. The pGEMT-*ahpC* product was verified by double-digestion with *BamH*I and *Hind*III enzymes. Afterward, *ahpC* gene was cloned in multiple cloning site between *BamH*I and *Hind*III in expression plasmid, pET-28a (+), which encodes for the 6xHis tag. The resulting recombinant plasmid was named pET-*ahpC* and was introduced in *E.coli* DH5α. The recombinant bacteria were screened via restriction enzyme digestion of plasmids and PCR**.** pET-*ahpC* was sequenced by Sanger sequence analysis method (Sentebiolab, Turkey)

(Supplemental information). pET-*ahpC* was subsequently transformed into the host *E. coli* BL21(DE3) competent cells (Novagen) for recombinant protein expression.

2.4. Expression and purification of recombinant AhpC

Expression and purification of recombinant AhpC (rAhpC) were performed as described by Okay et al. (Okay et al., 2012). *E. coli* BL21 (DE3) cells carrying pET-*ahpC* was grown in Luria Broth (LB; Merck, Germany) supplemented with kanamycin (30 μg/mL). When OD_{600} value of culture reached 0.5, isopropyl-β-D-galactopyranoside (IPTG; Sigma, Germany) was added to induce recombinant protein expression (1 mM final concentration). Incubation was carried out at 37 °C for 4 h in a shaker incubator at 200 rpm. Expression host cells were collected by centrifugation (5000 g for 5 min, at 4 °C). Subsequently, the harvested cells were resuspended in LEW buffer (Lysis-Equilibration-Washing buffer; 50 mM NaH_2PO_4, 300 mM NaCl, 8 M urea, pH 8.0). Next, cells were lysed using an ultrasonic probe (Bandelin-Sonoplus, Germany) at 60% amplitude, 10 s pulses at six intervals. Cellular debris was removed by centrifugation, and the supernatant containing recombinant protein was collected. Purification of the protein was performed by applying the supernatant to a Ni-NTA affinity column (Protino® Ni-TED 2000 packed columns, Macherey–Nagel, Germany) according to the supplier's instructions. Eluted proteins were concentrated by Amicon® ultrafiltration device (Merckmillipore, USA), sterilized through a 0.2 μm membrane filter, and stored at - 20 °C until use. Bradford's (Braford, 1976) method was used to quantify the recombinant protein.

2.5. Characterization of recombinant AhpC

1 The protein was further subjected to sodium dodecyl sulfate-polyacrylamide gel
2 electrophoresis (SDS–PAGE) and Western-blotting to analyze the expression. Briefly, a
3 purified protein sample was run on 4-12% SDS-polyacrylamide gels (Laemmli, 1970).
4 Coomassie Blue R-250 staining protocol was performed for one of the gels, and the other
5 was transferred to nitrocellulose membrane (0.45 μm) by processing via a modified
6 Towbin method (Towbin, 1979). The anti rAhpC antibody obtained from the 60th-day
7 serum of mice vaccinated with rAhpC, at a dilution factor of 1:400 (v/v) was used as the
8 primary antibody. Alkaline phosphatase (AP)-conjugated anti-mouse IgG (Sigma,
9 Germany) was used as the secondary antibody (at a dilution of 1:20.000 (v/v)). To
10 visualize protein bands on nitrocellulose membrane, AP Conjugate Substrate Kit (Bio-
11 Rad, CA, USA) was applied.

12 **2.6. Preparation of vaccine formulations**

13 A 1 mg/mL rAhpC stock solution was prepared in PBS. The antigen (rAhpC)
14 solution and adjuvant (Montanide 61VG, Seppic) components were mixed at a ratio of
15 2:3 (v/v) under aseptic conditions by vortexing for 2 mins. Prior to use, the sterility of
16 prepared vaccine formulations was tested using aerobic culture on LB-agar incubated at
17 37 °C for 48 hours.

18 **2.7. Animals and vaccination**

19 6-8 week old female BALB/c mice were immunized in animal experiments.
20 Animal experiments were performed under the approval of the Ethics Committee on
21 Animal Experimentation, Hacettepe University, Turkey (No: 2020/08-16). Animals were
22 immunized subcutaneously in groups of six with one of the following treatment
23 conditions:

1 - Group A (n=6): Adjuvant control group; immunized with 250 µL PBS – ISA 61VG mixture (2:3 v/v, administrated at day 0 and 15).
3 - Group B (n=6): BCG control group; immunized with 0.1 mL, $5x10^6$ CFU BCG vaccine (Serum Institute of India), given once (at day 0) and injected with 250 µL of PBS two times (administrated at day 15 and 30).
6 - Group C (n=6): BCG Prime – ISA 61VG Boost group; immunized with 0.1 mL prime BCG with $5x10^6$ CFU, given once (at day 0) and boosted with 250 µL total volume of ISA 61VG (administrated at day 15 and 30).
9 - Group D (n=6): Adjuvanted rAhpC group; immunized with 250 µL purified rAhpC formulated with ISA 61VG (2:3, v/v, administrated at day 0 and 15).
11 - Group E (n=6): BCG Prime – AhpC Boost group; immunized with 0.1mL prime BCG ($5x10^6$ CFU), given once (at day 0) and boosted with 250 µL purified rAhpC formulated with ISA 61VG (2:3, v/v, administrated at day 15 and 30).

14 The tail vein of mice was chosen for the collection of blood samples at day 0, 15, 30, 45, and 60. The collected serum samples were stored at - 20 °C until use. Mice were euthanized via cervical dislocation at day 60. The immunization schedule and blood collection times of the groups are illustrated in Figure 1.

18 **2.8. Detection of antibody response**

19 AhpC-specific IgG levels were measured by enzyme-linked immunosorbent assay (ELISA). 96-well plates were coated with rAhpC protein (1 µg/well). Sera collected from vaccinated mice were used as the primary antibody. Two-fold serial dilutions of primary antibodies (from 1:50 to 1:6400, v/v) were applied in plates in duplicates. Alkaline phosphatase-conjugated anti-mouse IgG (Sigma, USA) was used as a secondary antibody

at a dilution factor of 1:1000 (v/v). The AP Conjugate Substrate Kit was used as a colorimetric reagent (Bio-Rad, USA). Optical density was measured at 405 nm.

2.9. IL-12 assay

Mouse IL-12 ELISA Total Kit (Thermo Scientific) was used according to the supplier's instructions to measure the cellular immune response in the vaccinated mice. The sera collected from the vaccinated mice were used as the primary antibody, and the level of serum IL-12 was calculated via a standard curve.

2.10. Statistical analysis

ELISA data were analyzed by using the Graphpad Prism 8 software using two-way analysis of variance (ANOVA) and a posthoc test (Tukey's test). P values < 0.05 were considered as significant.

3. Results

3.1. Cloning of *ahpC* gene

The *ahpC* gene from *M. bovis* (588 bp, GenBank CP003494.1, location: 2400625 .. 2401212) was successfully amplified (Figure 2). Subsequently, the *ahpC* gene was cloned in pGEM-T Easy vector system and pET-28a(+) for gene amplification and recombinant protein purification, respectively.

3.2. SDS-PAGE and Western blot analyses of rAhpC protein

pET-28a(+) vector encoding *ahpC* was transformed into *E.coli* BL21(DE3) for rAhpC production. rAhpC produced in *E.coli* was purified using nickel columns. The molecular weight (MW) of the rAhpC (including His-tags) was predicted as 22.389 kDa using a web-based tool (ProtParam, https://web.expasy.org/protparam). The observed MW of the rAhpC protein on SDS-PAGE was approximately 25 kDa (Figure 3a). Protein-

specific sera were used as primary antibody in Western blot analysis. Antibodies in sera also bind ~50 kDa dimerized rAhpC protein (Figure 3b).

3.3. Humoral immune response against AhpC

Antibody-mediated immune responses depend on different functions of multiple classes of antibodies (i.e, IgM, IgA, IgG, and IgE). Among them, IgG is known with its antigen specific high affinity and also its ability for neutralization of the infectious pathogens as well as its Fc-mediated effector functions. On the other hand, its characteristics such as abundance and long half-life time in blood, and also interaction with differentiated memory B cells render immunoglobulin G as a good indicator for humoral immune responses (Galipeau et al., 2020).

In this study, quantitative detection of the humoral immune response against AhpC protein was tested using ELISA method. The total IgG level in collected sera of mice groups was evaluated at day 0, 15, 30, 45, and 60 (Figure 4) using two-way ANOVA and Tukey's test (Table 1).

All vaccination regimens were well tolerated by the mice groups. In Group A (adjuvant ISA 61 VG vaccination group), the anti-AhpC IgG was not detected until day 60. All other groups, on the other hand, showed a AhpC specific IgG response from day 30 indicating that BCG or adjuvanted AhpC vaccination requires at least 30 days to induce anti-AhpC antibodies. Introduction of second second dose adjuvanted AhpC elicited antibody production in Group D (adjuvanted rAhpC group), but it was not as high as in Group E (BCG prime – AhpC boost group). At day 45 and 60, the serum of mice in Group C (BCG Prime – ISA 61VG boost group) or Group B (BCG control Group) retained anti-AhpC IgG antibodies. Likewise, an day 45 and 60, increased anti-AhpC IgG

levels were detected in both Group D (Adjuvanted AhpC group) and Group E (BCG prime – AhpC boost group). The results indicate that administering the second dose of AhpC as a booster increases the anti-AhpC level up to 60 days (Figure 4).

Our results showed that vaccination with adjuvanted AhpC alone was more effective than ISA 61 VG alone (Group A vaccination group) and BCG alone (Group B vaccination group) at the end of 60 days ($p<0,001$ and $p<0,01$ respectively, Table 1). However, when adjuvanted AhpC was used as a booster to prime BCG vaccine, a more potent and sustainable humoral immune response was induced during the 60 day period (Figure 4 Table 1).

In Group E, single-dose adjuvanted AhpC vaccination after BCG prime immunization induced a stronger humoral response compared to Group D, which was immunized with two doses of adjuvanted AhpC ($p<0.001$, Figure 4, Table 1). Moreover, injection of a second booster dose of adjuvanted AhpC in Group E increased the serum antibody level more (at day 45).

In a nutshell, anti-AhpC IgG antibodies were induced both with AhpC vaccine alone and BCG primed – AhpC booster vaccine regimens at day 60.

3.4. Cellular immune responses induced by vaccinations

The change in serum IL-12 level in the vaccination groups at day 0, 15, 30, 45, and 60 (Figure 5) was wvaluated (Table 2).

In all mice groups, the srum IL-12 was at basal level at day 0. At day 15, an increase in serum IL-12 level was observed in all groups with the highest value measured in adjuvanted AhpC treated group. The adjuvant effect of booster ISA 61 VG is clearly witnessed (at day 30, 45 and 60) in the differences in serum IL-12 level between Group

B (BCG control group) and Group C (BCG prime – ISA 61 VG boost group). The highest IL-12 levels were achieved in Group E after first AhpC bosster as well as after second AhpC booster. At day 60, a decrease in serum IL-12 was observed in all groups, yet still the highest serum IL-12 level was measured in Group E (BCG prime – AhpC bosst group) (Figure 5).

At day 15, although an increase in serum IL-12 level was observed in all groups after the first vaccination, the highest titer was realised in adjuvanted AhpC vaccination group (Group D). On the contrast, an increase in serum IL-12 titers was seen in all groups except adjuvanted AhpC vaccination group (Group D) at day 30. Interestingly, a second booster dose of adjuvanted AhpC led to a decrease in serum IL-12 concentration, unlike the first booster dose, which raised the IL-12 levels. At day 30, 45 and 60, Group C (BCG prime – ISA 61 VG boost group) had relatively higher levels of IL-12 as compared to Group B (BCG control group) ($p<0,01$, $p<0,001$ and $p<0,0001$, respectively) due to the adjuvant effect of Montanide ISA 61 VG. At days 45 and 60, the serum IL-12 level in adjuvanted AhpC vaccination (Group D) was less than Group E (BCG prime – AhpC boost group).

In summary, it can be said that adjuvanted AhpC did not elicit strong immune responses when it was administrated as alone; however, an immunostimulation enhancer effect was observed when it was used as a booster vaccine in BCG prime immunized mice.

4. Discussion

Currently, BCG is widely used in many countries in the childhood vaccination program to prevent severe forms of TB in children. However, BCG vaccination is seen not sufficient aginst TB infection in adults (World Health Organization, 2020). Therefore,

1 efforts in the prevention of TB are mainly focused on the development of new vaccines,
2 new drugs, or innovative treatment strategies. Currently, various new drugs, vaccines and
3 combination regimens are under investigation in clinical trials.

4 In this study, a new recombinant vaccine formulation composed of AhpC and an
5 oil-based adjuvant Montanide ISA 61 VG was administered to mice as a subunit vaccine
6 alone and as a booster after BCG-prime vaccination.

7 Although AhpC is a protein with a molecular wight of ~25 kDa, we observed two
8 distinct bands (~25 kDa and ~50 kDa) in SDS-PAGE as shown in the study of O'Riordan
9 et al. (2012). The band of 50 kDa was due to the possible dimerization of AhpC between
10 two cysteine sulfhydryls in protein structure (Hillas et al., 2000; Chauhan and Mande,
11 2002). Two bands at 25 and 50 kDa were also detected in Western blot, which belongs to
12 AhpC and its dimer form, respectively. Although this lane was lysate of non-IPTG-
13 induced *E.coli* BL21(DE3) harboring pET-*ahpC*, the protein bands were probably a result
14 of phenomenon known as the leaky expression of T7promoter – T7RNA polymerase
15 system (McCutcheon, 2018).

16 Disperse systems, chemical or biological molecules can be used as adjuvants in
17 order to enhance the immunogenicity of an antigen. Studies have been conducted to
18 evaluate adjuvant's potential use in the vacines against infectious diseases, cancer and
19 autoimmune diseases (Shah et al., 2015). Montanide adjuvant system includes mineral or
20 non-mineral oils, a mannitol-based surfactant, and purified oleic acid from vegetable
21 origin (Jang et al., 2010). They are classified as emulsions, micro-emulsions, and
22 polymeric gels according to their preparation technology (Seppic, 2017). Montanide ISA
23 61 VG adjuvant is a ready-to-use mineral oil-based stable w/o emulsion formulation, and

1 it induces high-level and long-lasting immune responses in animals (Khorasani et al.,
2 2016).

3 Since subunit vaccines contain only the antigenic parts of the pathogen, replication
4 in the host is not possible. Therefore, they have advantages in terms of safety
5 considerations. On the other hand, certain drawbacks such as the requirement of multiple
6 doses and co-administration of adjuvant(s) to elicit a vigorous humoral or cellular
7 immune response against the antigen(s) of interest hinders the use of vaccines (Hansson
8 et al., 2000). In this study, no anti-AhpC antibodies were detected in adjuvanted AhpC
9 vaccination group (Group D) 15 days after the first dose but rather, the anti-AhpC
10 antibodies were detected after the second dose adjuvanted AhpC administration (boost
11 injection). At day 60 of the study, anti-AhpC antibodies reached maximum levels 4 weeks
12 after booster injection, also reported by O'Riordan et al. (2012). Although more studies
13 are required for a better understanding of the mechanism of action of adjuvants used in
14 vaccine formulations, it is believed that water-in-oil emulsion-based adjuvants induce
15 local inflammation and increase the recruitment and activation of antigen-presenting cells
16 (Leroux-Roels, 2010). Enhancer effect of ISA 61 VG adjuvant on antibody responses was
17 reported by others (İz et al., 2018). We observed this effect also in our study by comparing
18 the results of Group B (BCG control group) and Group C (BCG prime – ISA 61 VG boost
19 group). First and second booster doses of ISA 61 VG given to BCG-prime vaccinated
20 mice enhanced the production of anti-AhpC IgG at day 30 and 45, respectively (Table 1,
21 $p<0.05$). At the end of immunization (day 60), serum anti-AhpC antibody level of Group
22 C was higher than Group B (Table 1, $p<0.001$).

23 The importance of cell-mediated responses for immune protection against
24 intracellular pathogens such as *M. tuberculosis* is well known. Cytokines such as

1 interferon-γ (IFN-γ), tumor necrosis factor α (TNF-α), and interleukin 12 (IL-12) play a
2 vital role in protective cell-mediated immune response against TB disease (Kaufmann,
3 2008). Therefore, the selection of appropriate adjuvant is a critical step for subunit
4 vaccine formulations since either humoral or cellular immune responses can be induced
5 depending on the type of adjuvant used in the vaccine formulation. In addition to
6 stimulating the antibody responses, Montanide ISA 61 VG adjuvant also has a strong
7 inducer effect on cellular immune response (Ibrahim et al., 2015). Our observation of
8 serum IL-12 levels of the mice groups revealed an outcome that is different from the
9 results of IgG responses. Unlike with the antibody response which constantly increased
10 up to day 60, the serum IL-12 level decreased after second booster doses at day 30 (only
11 for Group D), at day 45 (for all groups with the exception of Group E) and day 60 (for all
12 groups). This observation could be attributed to a negative feedback loop, due to the
13 release of immunoregulatory cytokines or imbalance between regulatory and effector T
14 cell subsets, as suggested by Begg et al. (2019). Nevertheless, the rise in serum IL-12
15 level in Group A demonstrate the cellular immune response enhancing ability of the
16 adjuvant. Between Group B and Group C, the latter had relatively higher levels of serum
17 IL-12 at day 30, 45 and 60.

18 A study conducted by Karonga Prevention Trial Group to evaluate the effect of
19 revaccination with BCG in humans has revealed that a second BCG vaccination could not
20 provide any protection against tuberculosis. It was suggested that boosting of immune
21 responses in BCG-primed vaccinations could possibly enhance BCG immunity (Valdés
22 et al., 2019). In this light, Yang et al. (2016) showed in their study that the use of BCG
23 prime – subunit recombinant protein vaccine immunization strategy could enhance the
24 cellular immune response in mice. Different boosting strategies and the importance of

1 prime – boost immunization in vaccination against TB were well reviewed by Dalmia and
2 Ramsay (2012). Overall, immune response against *M. tuberculosis* by a two-stage
3 vaccination regimen based on priming with BCG and boosting with the most effective
4 subunits seems to be the most promising approach. When the effect of adjuvanted AhpC
5 used as subunit vaccine alone was compared with AhpC used as a booster to BCG prime
6 in BALB/c mice, it was realised that a single dose adjuvanted AhpC could not induce
7 anti-AhpC antibody response unless supplemented with a second dose booster. However,
8 a single dose AhpC as a booster after BCG – prime vaccination elicited higher IgG
9 responses.

10 When it comes to cellular immune response, it was observed that group treated
11 with a single dose of adjuvanted AhpC induced a stronger IL-12 response as compared to
12 adjuvant and BCG vaccination groups. But afterwards, second dose adjuvanted AhpC
13 administration caused a decrease in serum IL-12 level. Based on this observation,
14 adjuvanted AhpC vaccination could be said to induce the highest level of IL-12. However,
15 a more robust profile for strong humoral responses was obtained in BCG prime – AhpC
16 boost vaccination group (Group E), suggesting that 'BCG prime – AhpC boost'
17 vaccination could be a useful strategy for the development of a TB vaccine against
18 tuberculosis disease. Further bacterial challenge studies are needed to evaluate the
19 immunoprotective effect of BCG prime – AhpC boost vaccination strategy against
20 tuberculosis disease caused by virulence strain of *M. bovis* or *M. tuberculosis*.

21 In this study, we evaluated the effect of antioxidant enzyme, AhpC, on humoral
22 and cellular immune responses in BALB/c mice for a period of 60 days. A new
23 recombinant vaccine formulation composed of AhpC protein antigen and an oil-based
24 adjuvant Montanide ISA 61 VG was administered to mice as a subunit vaccine

formulation alone and as a booster for BCG – prime vaccination. Based on our results, the BCG prime – AhpC boost vaccination strategy prolonged both humoral and cellular immune response. It can be concluded that, AhpC, an antioxidant protein, is a promising subunit vaccine antigen when used in BCG prime-AhpC protein boost vaccination strategy against TB.

Acknowledgements

The authors thank Assoc. Prof. Dr. Alpaslan Alp (Hacettepe University Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey) for kindly providing isolated and purified genomic DNA of *M. bovis* (ATCC 35743, GenBank CP003494.1, USA).

Conflict of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Funding

This work was supported by Hacettepe University Scientific Research Project Coordination Unit (Project numbers: THD-2017-15688 and TDK-2017-16102).

References

Begg DJ, Dhungyel O, Naddi A, Dhand NK, Plain KM et al. (2019). The immunogenicity and tissue reactivity of *Mycobacterium avium subsp paratuberculosis* inactivated whole cell vaccine is dependent on the adjuvant used. Heliyon 5: e01911. doi: 10.1016/j.heliyon.2019.e01911.

Bradford MM (1976). A rapid and sensitive method for the quantitation of microgramquantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72: 248-254. doi: 10.1016/0003-2697(76)90527-3.

Chauhan R, Mande SC (2002). Site-directed mutagenesis reveals a novel catalytic mechanism of *Mycobacterium tuberculosis* alkylhydroperoxidase C. Biochemical Journal 367 (1): 255-261. doi: 10.1042/bj20020545.

Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E et al (1994). Efficacy of BCG vaccine in the prevention of tuberculosis: Meta-analysis of the published literature. JAMA. 271 (9), 698-702. doi:10.1001/jama.1994.03510330076038.

Dalmia N, Ramsay AJ (2012). Prime-boost approaches to tuberculosis vaccine development. Expert Review of Vaccines 11 (10): 1221-1233. doi: 10.1586/erv.12.94.

Echeverria-Valencia G, Flores-Villalva S, Espitia CI (2018). Virulence factors and pathogenicity of Mycobacterium. In: Ribón W (editor). Mycobacterium - Research and Development. London: United Kigdom: InTech, pp. 231– 255.

Evans JT, Smith EG, Banerjee A, Smith RMM, Dale J et al. (2007). Cluster of human tuberculosis caused by *Mycobacterium bovis*: evidence for person-to-person transmission in the UK. The Lancet 369: 1270-1276. doi: 10.1016/S0140-6736(07)60598-4.

Fatima S, Kumari A, Das G, Dwivedi VP (2020). Tuberculosis vaccine: A journey from BCG to present. Life Sciences 252: 117594. doi: 10.1016/j.lfs.2020.117594.

1 Forrellad MA, Klepp LI, Gioffré A, y García JS, Morbidoni HR et al. (2013). Virulence
2 factors of the *Mycobacterium tuberculosis* complex. Virulence 4 (1): 3-66. doi:
3 10.4161/viru.22329.
4 Grange JM (2001). *Mycobacterium bovis* infection in human beings. Tuberculosis 81
5 (1/2): 71-77. doi: 10.1054/tube.2000.0263.
6 Hansson M, Nygren PA, Stahl S (2000). Design and production of recombinant subunit
7 vaccines. Biotechnology and Applied Biochemistry 32 (2): 95-107. doi:
8 10.1042/BA20000034.
9 Hillas PJ, del Alba FS, Oyarzabal J, Wilks A, de Montellano PRO (2000). The AhpC and
10 AhpD antioxidant defense system of *Mycobacterium tuberculosis*. Journal of Biological
11 Chemistry. 275 (25): 18801–18809. doi: 10.1074/jbc.M001001200.
12 Ibrahim El-SE, Gamal WM, Hassan AI, Mahdy SEl-D, Hegazy AZ et al. (2015).
13 Comparative study on the immunopotentiator effect of ISA 201, ISA 61, ISA 50, ISA 206
14 used in trivalent foot and mouth disease vaccine. Veterinary World 8 (10): 1189-1198.
15 doi: 10.14202/vetworld.2015.1189-1198.
16 Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA (2020). Humoral Responses and
17 Serological Assays in SARS-CoV-2 Infections. Frontiers in Immunology 11: 610688.
18 doi: 10.3389/fimmu.2020.610688.
19 Iz SG, Sağlam Metiner P, Kımız I, Kayalı Ç, Deliloğlu Gürhan SI (2018). Polyclonal
20 antibody production against hapten-structured KDN molecule by using different
21 adjuvants alternative to freund's adjuvant. European Journal of Therapeutics 24 (2): 106-
22 111. doi: 10.5152/EurJTher.2018.400.
23 Jang SI, Lillehoj HS, Lee SH, Lee KW, Park MS et al (2010). Immunoenhancing effects
24 of Montanide ISA oil-based adjuvants on recombinant coccidia antigen vaccination

against Eimeria acervulina infection. Veterinary Parasitology 172: 221–228. doi: 10.1016/j.vetpar.2010.04.042.

Kanipe C, Palmer MV (2020). *Mycobacterium bovis* and you: A comprehensive look at the bacteria, its similarities to *Mycobacterium tuberculosis*, and its relationship with human disease. Tuberculosis 125: 102006. doi: 10.1016/j.tube.2020.102006.

Kaufmann SHE, Parida SK (2008). Tuberculosis in Africa: learning from pathogenesis for biomarker identification. Cell Host & Microbe 4 (3): 219-228. doi: 10.1016/j.chom.2008.08.002.

Khorasani A, Madadgar O, Soleimanjahi H, Keyvanfar H, Mahravani H (2016). Evaluation of the efficacy of a new oil-based adjuvant ISA 61 VG FMD vaccine as a potential vaccine for cattle. Iranian Journal of Veterinary Research 17 (1): 8-12.

Laemmli UK (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (5259): 680-685. doi: 10.1038/227680a0.

Leroux-Roels G (2010). Unmet needs in modern vaccinology: Adjuvants to improve the immune response. Vaccine. 28: C25-C36. doi: 10.1016/j.vaccine.2010.07.021.

McCutcheon SR, Chiu KL, Lewis DD, Tan C (2018). CRISPR-Cas Expands Dynamic Range of Gene Expression From T7RNAP Promoters. Biotechnology Journal 13 (5): e1700167. doi: 10.1002/biot.201700167.

Michel AL, Müller B, van Helden PD (2010). *Mycobacterium bovis* at the animal–human interface: A problem, or not? Veterinary Microbiology. 140 (3-4): 371-381. doi: 10.1016/j.vetmic.2009.08.029.

Okay S, Özcengiz E, Gürsel I, Özcengiz G (2012). Immunogenicity and protective efficacy of the recombinant Pasteurella lipoprotein E and outer membrane protein H from

Pasteurella multocida A: 3 in mice. Research in Veterinary Science 93 (3): 1261-1265. doi: 10.1016/j.rvsc.2012.05.011.

O'Riordan AA, Morales VA, Mulligan L, Faheem N, Windle HJ et al. (2012). Alkyl hydroperoxide reductase: A candidate Helicobacter pylori vaccine. Vaccine. 30 (26): 3876-3884. doi:10.1016/j.vaccine.2012.04.002.

Rodriguez-Campos S, Smith NH, Boniotti MB, Aranaz A (2014). Overview and phylogeny of *Mycobacterium tuberculosis* complex organisms: Implications for diagnostics and legislation of bovine tuberculosis. Research in Veterinary Science 97: S5-S19. doi: 10.1016/j.rvsc.2014.02.009.

Seppic (2017). Montanide™. https://www.seppic.com/sites/seppic/files/2017/02/28/seppic-montanide.pdf (accessed 10 February 2021).

Shah RR, Brito LA, O'Hagan DT, Amiji MM (2015). Emulsions as Vaccine Adjuvants. In: Foged C, Rades T, Perrie Y, Hook S (editors). Subunit Vaccine Delivery. Springer, New York: pp. 59-76.

Sunder S, Lanotte P, Godreuil S, Martin C, Boschiroli M et al. (2009). Human-to-human transmission of tuberculosis caused by *Mycobacterium bovis* in immunocompetent patients. Journal of Clinical Microbiology 47 (4): 1249-1251. doi: 10.1128/JCM.02042-08.

Towbin H, Staehelin T, Gordon J (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences 76 (9): 4350-4354. doi: 10.1073/pnas.76.9.4350.

Valdés I, Lazo L, Hermida L, Guillén G, Gil L (2019). Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus? Frontiers in Immunology 10: 1956. doi: 10.3389/fimmu.2019.01956.

Verma H, Nagar S, Vohra S, Pandey S, Lal D, Negi RK, Lal R, Rawat CD (2021). Genome analyses of 174 strains of *Mycobacterium tuberculosis* provide insight into the evolution of drug resistance and reveal potential drug targets. Microbial Genomics 7 (3): 000542. doi: 10.1099/mgen.0.000542.

Whitlow E, Mustafa AS, Hanif, SNM (2020). An overview of the development of new vaccines for tuberculosis. Vaccines 8 (4): 586. doi: 10.3390/vaccines8040586.

Wilson T, de Lisle GW, Marcinkeviciene JA, Blanchard JS, Collins DM (1998). Antisense RNA to ahpC, an oxidative stress defence gene involved in isoniazid resistance, indicates that AhpC of *Mycobacterium bovis* has virulence properties. Microbiology 144 (10): 2687-2695. 10.1099/00221287-144-10-2687.

Wilson TM, Collins DM (1996). ahpC, a gene involved in isoniazid resistance of the *Mycobacterium tuberculosis* complex. Molecular Microbiology 19 (5): 1025-1034. doi: 10.1046/j.1365-2958.1996.449980.x

Wong CF, Shin J, Manimekalai MSS, Saw WG, Yin Z, Bhushan S, Kumar A, Ragunathan P, Grüber G (2017). AhpC of the mycobacterial antioxidant defense system and its interaction with its reducing partner Thioredoxin-C. Scientific Reports 7: 5159. doi: 10.1038/s41598-017-05354-5.

World Health Organization (2020). Global Tuberculosis Report 2020. Geneva: World Health Organization: Licence: CC BY-NC-SA 3.0 IGO.

Yang E, Gu J, Wang F, Wang H, Shen H et al. (2016). Recombinant BCG prime and PPE protein boost provides potent protection against acute *Mycobacterium tuberculosis* infection in mice. Microbial Pathogenesis 93: 1-7.

Figures and Tables



Figure 1. Schematic illustration of immunization schedule. Blood samples were collected just before vaccine administration at days 0, 15 and 30.

Abbr. PBS, Phosphate Buffered Saline.



Figure 2. Agarose gel image of *ahpC* gene was amplified by PCR from *M.bovis* genome. M: DNA marker (G571A, Promega); 1,2: PCR amplified *ahpC*; 3: Negative control PCR tube.

Dashed arrows show the expected amplicon size for the AhpC gene (588 bp, GenBank CP003494.1, location: 2400625 .. 2401212).



Figure 3. Gel images of SDS-PAGE analyis by Coomassie blue staining **(A)** and Western blot **(B)**. The primary antibodies used in WB were obtained from the 60th day serum of AhpC vaccination group (Group D).

M: Prestained protein ladder (Bio-Helix, PM007),

1: Lysate of *E.coli* carrying pET-*ahpC* (IPTG non-induced),

2: Lysate of *E.coli* carrying pET-*ahpC* (IPTG-induced),

3: Flow-through fraction,

4-5: First and second washing fractions, respectively,

6-7: First and second elutions of recombinant AhpC protein, respectively.

1
2
3
4
5
6
7
8



9 **Figure 4.** Measured OD_{405} values of total serum IgG in BALB/c mice. Samples were diluted by
10 a dilution factor of 1:200. PBS was used as blank solution and measured OD_{405} value of PBS has
11 been subtracted from all absorbances.

12 ***Abbr.*** PBS; phosphate buffered saline.

13 *Group A: PBS – ISA 61VG (turquoise blue); Group B: BCG prime – PBS boost (Navy blue);*
14 *Group C: BCG Prime – ISA 61VG Boost (red); Group D: rAhpC – ISA 61VG (orange); Group*
15 *E: BCG Prime – AhpC Boost (green).*

Table 1. Analysis of variance (ANOVA) for serum IgG levels in BALB/c mice groups.

Vaccination Groups	Day 0	Day 15	Day 30	Day 45	Day 60
Group A – Group B	NS	NS	*	***	****
Group A – Group C	NS	NS	**	****	****
Group A – Group D	NS	NS	**	**	***
Group A – Group E	NS	NS	****	****	****
Group B – Group C	NS	NS	*	*	***
Group B – Group D	NS	NS	**	*	**
Group B – Group E	NS	NS	****	****	****
Group C – Group D	NS	NS	**	*	**
Group C – Group E	NS	NS	****	****	****
Group D – Group E	NS	NS	***	****	****

Note: PBS measurements were subtracted from those of vaccination groups. Day 0 is considered as the point of pre-immunization. *p<0,05. **p<0,01. ***p<0,001. ****:p<0,0001; NS: not significant.

Group A: PBS – ISA 61VG (turquoise blue); Group B: BCG prime – PBS boost (Navy blue); Group C: BCG Prime – ISA 61VG Boost (red); Group D: rAhpC – ISA 61VG (orange); Group E: BCG Prime – AhpC Boost (green).



Figure 5. Serum IL-12 concentrations of BALB/c mice at different time intervals.

Abbr. Conc; concentration.

Group A: PBS – ISA 61VG (turquoise blue); Group B: BCG prime – PBS boost (Navy blue); Group C: BCG Prime – ISA 61VG Boost (red); Group D: rAhpC – ISA 61VG (orange); Group E: BCG Prime – AhpC Boost (green).

1

Table 2. Analysis of variance (ANOVA) for serum IL-12 levels in BALB/c mice groups.

Vaccination Groups	Day 0	Day 15	Day 30	Day 45	Day 60
Group A – Group B	NS	****	****	****	****
Group A – Group C	NS	****	****	****	****
Group A – Group D	NS	****	****	****	****
Group A – Group E	NS	****	****	****	****
Group B – Group C	NS	NS	**	**	****
Group B – Group D	NS	****	****	****	****
Group B – Group E	NS	NS	****	****	****
Group C – Group D	NS	****	***	*	NS
Group C – Group E	NS	NS	****	****	****
Group D – Group E	NS	****	***	****	****

Note: Day 0 is considered as the time point of pre-immunization. *p<0,05. **p<0,01. ***p<0,001. ****:p<0,0001; NS: not significant.

Group A: PBS – ISA 61VG (turquoise blue); Group B: BCG prime – PBS boost (Navy blue); Group C: BCG Prime – ISA 61VG Boost (red); Group D: rAhpC – ISA 61VG (orange); Group E: BCG Prime – AhpC Boost (green).